Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
ASX:MYX
Price:
5.74 AUD
-9.89%
Market Closed
Updated:
May 20, 2024
Mayne Pharma Group Ltd
Accrued Liabilities
|
Mayne Pharma Group Ltd
Accrued Liabilities Peer Comparison
Comparables:
RCE
NEU
BOT
PBP
C
CU6
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Accrued Liabilities
AU$195.9m
|
CAGR 3-Years
41%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Accrued Liabilities
AU$227.8k
|
CAGR 3-Years
16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Probiotec Ltd
ASX:PBP
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Accrued Liabilities
AU$1m
|
CAGR 3-Years
144%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Mayne Pharma Group Ltd's Accrued Liabilities?
Accrued Liabilities
195.9m
AUD
195.9m
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Accrued Liabilities amounts to 195.9m AUD.
What is Mayne Pharma Group Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
20%
20%
Over the last year, the Accrued Liabilities growth was 73%. The average annual Accrued Liabilities growth rates for Mayne Pharma Group Ltd have been 41% over the past three years , 20% over the past five years .
You don't have any saved screeners yet
